Enhancing return-to-work in cancer patients, development of an intervention and design of a randomised controlled trial by Tamminga, SJ et al.
 
 
University of Birmingham
Enhancing return-to-work in cancer patients,
development of an intervention and design of a
randomised controlled trial
Tamminga, SJ; de Boer, AG; Verbeek, JH; Taskila, Taina; Frings-Dresen, MH
DOI:
10.1186/1471-2407-10-345
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Tamminga, SJ, de Boer, AG, Verbeek, JH, Taskila, T & Frings-Dresen, MH 2010, 'Enhancing return-to-work in
cancer patients, development of an intervention and design of a randomised controlled trial', BMC Cancer, vol.
10, 345. https://doi.org/10.1186/1471-2407-10-345
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
Checked July 2015
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
Tamminga et al. BMC Cancer 2010, 10:345
http://www.biomedcentral.com/1471-2407/10/345
Open AccessS T U D Y  P R O T O C O LStudy protocolEnhancing return-to-work in cancer patients, 
development of an intervention and design of a 
randomised controlled trial
Sietske J Tamminga*1, Angela GEM de Boer1, Jos HAM Verbeek1,2, Taina Taskila1,3 and Monique HW Frings-Dresen1
Abstract
Background: Compared to healthy controls, cancer patients have a higher risk of unemployment, which has negative 
social and economic impacts on the patients and on society at large. Therefore, return-to-work of cancer patients 
needs to be improved by way of an intervention. The objective is to describe the development and content of a work-
directed intervention to enhance return-to-work in cancer patients and to explain the study design used for evaluating 
the effectiveness of the intervention.
Development and content of the intervention: The work-directed intervention has been developed based on a 
systematic literature review of work-directed interventions for cancer patients, factors reported by cancer survivors as 
helping or hindering their return-to-work, focus group and interview data for cancer patients, health care professionals, 
and supervisors, and vocational rehabilitation literature. The work-directed intervention consists of: 1) 4 meetings with 
a nurse at the treating hospital department to start early vocational rehabilitation, 2) 1 meeting with the participant, 
occupational physician, and supervisor to make a return-to-work plan, and 3) letters from the treating physician to the 
occupational physician to enhance communication.
Study design to evaluate the intervention: The treating physician or nurse recruits patients before the start of initial 
treatment. Patients are eligible when they have a primary diagnosis of cancer, will be treated with curative intent, are 
employed at the time of diagnosis, are on sick leave, and are between 18 and 60 years old. After the patients have given 
informed consent and have filled out a baseline questionnaire, they are randomised to either the control group or to 
the intervention group and receive either care as usual or the work-directed intervention, respectively. Primary 
outcomes are return-to-work and quality of life. The feasibility of the intervention and direct and indirect costs will be 
determined. Outcomes will be assessed by a questionnaire at baseline and at 6, 12, 18, and 24 months after baseline.
Discussion: This study will provide information about the effectiveness of a work-directed intervention for cancer 
patients. The intention is to implement the intervention in normal care if it has been shown effective.
Trial registration: NTR1658
Background
Since the survival rates of cancer have increased consid-
erably in recent years, the long-term side effects of cancer
and cancer-related treatments may impact survivors'
capabilities to regain normal lives. This implies that some
forms of cancer are becoming chronic diseases entailing
both poorer overall quality of life compared to the general
population and disabling long-term residual symptoms,
such as fatigue, depression, pain, and functional limita-
tions [1-3]. One aspect of regaining a normal life after
cancer is returning to work, which is often seen by cancer
survivors as an important part of recovery [4-6]. Further-
more, the loss of work of cancer survivors is associated
with lower quality of life, lower self-esteem, and worse
financial situations [7,8]. Unfortunately, not all cancer
survivors return-to-work. A meta-analysis showed that
the risk of unemployment is 37% higher for cancer survi-
vors compared to healthy controls [9]; cancer survivors
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Page 2 of 9also experience work limitations [10,11]. The employer
and society at large are also affected due to absenteeism,
disability pensions, and loss of productivity [12]. Further-
more, cancer survivors get little advice from their treating
physicians about return-to-work issues, and they experi-
ence a lack of guidance from their general practitioners or
occupational physicians as well [13,14]. Considering
these negative work-related side effects for cancer survi-
vors and the lack of attention toward these problems,
there is ample room to improve return-to-work with an
appropriate intervention.
A systematic review of the literature [15] concerning
work-directed interventions for cancer patients showed
that well-developed work-directed interventions are lim-
ited and that the methodological quality of these studies
is moderate. This indicates that a new intervention needs
to be developed and that its effectiveness on return-to-
work and quality of life should be determined by a ran-
domised controlled trial. Considering the financial
impacts on cancer patients and society at large, the direct
and indirect costs should also be taken into account.
Return-to-work is only one aspect of survivor care and
it should not be dealt with in isolation. Therefore, we
developed the intervention in such a way that it fits the
shared-care model for cancer survivor care [16]. This
model encompasses a work-directed intervention inte-
grated into cancer care as integrated into the occupa-
tional physician or general practitioner's care,
establishing active communication between these health
care professionals.
Objective
The objective is to describe the development and content
of a work-directed intervention to enhance return-to-
work in cancer patients and to explain the study design
used for evaluating the effectiveness of the intervention.
Development of the intervention
The development of the work-directed intervention is
based on the following: 1) a systematic review concerning
the content of work-directed interventions for cancer
patients, 2) factors reported by cancer survivors as help-
ing or hindering their return-to-work, 3) focus group
data of cancer survivors and of supervisors regarding
return-to-work after cancer, 4) vocational rehabilitation
literature, and 5) semi-structured interviews with health
care professionals.
First, the systematic review described the content of
work-directed interventions for cancer patients on the
basis of the two most important prognostic factors for
return-to-work that can be directly altered by a work-
directed intervention: self-perceived work ability and
physical workload [5,17]. Of the 19 included studies, 18
addressed work ability and 6 addressed physical work-
load. The following interventions to address work ability
proved to be suitable: making a return-to-work plan,
individual counselling/structural guidance, and cognitive
behavioural therapy, and provision of an educational leaf-
let. The interventions that were shown to be suitable to
address physical workload were: workplace accommoda-
tions and occupational or vocational training.
Second, we incorporated factors reported by cancer
survivors as helping or hindering their return-to-work.
These factors were measured in a prospective cohort
study of Spelten et al. [18] with two-open questions:
"what or whom helped you the most with regard to work
resumption or continuing work?" and "what or whom hin-
dered you the most with regard to work resumption and
continuing work" [18]. Cancer survivors answered these
open-ended questions at 6, 12, and 18 months after their
first day of sick leave. We used the International Classifi-
cation of Functioning (ICF) as a theoretical framework to
categorise the answers into factors underlying work-
related disability: body structure and functioning, envi-
ronment-related factors, and person-related factors
[19,20]. The most frequently reported factor that aided in
return-to-work in the category of body structure and
functioning was general health; the most frequently
reported hindering factor was fatigue. With regard to
environment-related factors, managers, colleagues, and
family were the most frequently reported helping factors
and workload a hindering factor. For person-related fac-
tors, personality was the most frequently reported help-
ing factor, and distrust in the manager was a hindering
factor.
Third, the experiences of cancer survivors and supervi-
sors regarding return-to-work after cancer were assessed
in three focus groups [14]. A total of 7 cancer survivors
and 6 supervisors participated in the focus groups. The
following themes were reported by cancer survivors as
being the most important: 1) contact with and support
from colleagues and supervisors, 2) the occupational phy-
sician's and other physician's advice and expertise, and 3)
knowledge of the long-term consequences of cancer, such
as fatigue and cognitive problems. The following themes
were reported by supervisors as being the most impor-
tant: 1) their own role and that of the occupational physi-
cian, 2) return-to-work aspects such as work
accommodations, and 3) communication with all stake-
holders. The main findings of these focus groups were
that support from colleagues and supervisors aids in
return-to-work. Lack of knowledge and advice from
occupational physicians and lack of communication
between all stakeholders hinders return-to-work [14].
Fourth, because the occupational physician is legalised
to advise about the return-to-work of sick-listed employ-
ees in the Netherlands, he or she should be part of the
intervention. In addition, employer participation is essen-
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Page 3 of 9tial for preventing impediments. For instance, for the
implementation of workplace accommodations, it is
important that the employee, employer, and occupational
physician agree. Furthermore, the intervention should be
carried out close to the workplace and in collaboration
with all stakeholders [21].
Fifth, semi-structured interviews with a radiotherapist
and four oncology nurses from four different depart-
ments in the Netherlands were held to determine the best
way to integrate the intervention into usual cancer care.
The health care professionals stated that the intervention
should be integrated into psycho-oncological care. This
seemed to be feasible based on the results of our system-
atic review [15].  The interviewees' nurses stated that they
lack the knowledge to provide this kind of care but that a
training course would help to provide this knowledge.
Furthermore, the interviewed nurses and radiotherapist
believed that the intervention should be carried out indi-
vidually because of variations in treatment, survival, and
importance of work. In addition, the different factors
reported by cancer survivors as helping or hindering their
return-to-work also confirm the need to provide individ-
ual interventions. The interviewees stated that the psy-
cho-oncological care of cancer patients varies
enormously between hospital departments with respect
to content, length, duration, extensiveness, and provider.
These differences also hold for return-to-work, which is
not addressed structurally by any of the departments.
However, the interviewees believed that cancer patients
need structural guidance in their return-to-work process.
To achieve this guidance, they advised that meetings need
to be scheduled and that communication with the occu-
pational physician should be improved.
Content of the intervention
Incorporation of the findings described above resulted in
a work-directed intervention that encompasses: 1) 4
meetings of 15 minutes each will be held at the hospital as
part of the normal consulting hour to start early voca-
tional rehabilitation. These meetings will be carried out
as part of normal psycho-oncological care by an oncology
nurse, social worker or nurse practitioner. In this article,
we will refer to these people as the nurse. Since usual care
differs between hospital departments, the organisation of
these meetings may vary slightly, 2) one meeting with the
participant, the occupational physician, and the supervi-
sor will be held to make a return-to-work plan, and 3)
three letters will be send to the occupational physician to
enhance communication; two will be from the treating
physician and one from the nurse.
1) Meetings at the hospital
The aim of the first meeting is to make a list of potential
problems concerning return-to-work and to plan the
intervention that best suits the individual participant.
The first meeting will take place a few weeks after diagno-
sis, and the nurse will begin by taking a short work-anam-
nesis. Thereafter, the nurse will give guidance regarding
the best way to inform colleagues and supervisors about
the participant's illness and to keep them informed dur-
ing treatment/aftercare. Furthermore, the participant will
receive an informational leaflet about cancer [22]. An
educational leaflet that consists of 10 steps of advice [23]
will be given to the participant and will be used as a
guideline for the intervention. Scheduling of the second
meeting will depend on the diagnosis, treatment, and
preference of the participant; it will be scheduled for a
maximum of 10 months after the first meeting. The aim
is to schedule this meeting two months before the partic-
ipant is expected to return-to-work. This would largely
occur at the end of medical treatment, because most can-
cer patients return-to-work thereafter [18]. However, if a
participant wants to return-to-work during treatment,
the second meeting will be scheduled two months before
the return-to-work is expected.
The second meeting starts with a recapitulation of the
topics discussed at the first meeting. Then, barriers to
return-to-work will be identified, and actions to remove
these barriers will be discussed. This information will be
sent to the occupational physician. The identification of
barriers to return-to-work and actions to remove these
barriers are based on the work-anamnesis, physical, and
psychosocial restrictions, coping, individual importance
of work, participant preference regarding the return-to-
work, and the most important prognostic factors for
returning to work, such as, older age, lower education,
and blue collar work.
The aim of the third and fourth meetings is to evaluate
the process of return-to-work. The third meeting will be
scheduled for a maximum of 2 months after the second
meeting because during the actual return-to-work, differ-
ent problems might arise. The barriers to return-to-work
and actions to remove these barriers that were discussed
in the second meeting will be evaluated. If a return-to-
work plan has been made, it will be discussed. If neces-
sary, the return-to-work plan will be altered, and extra
information or advice will be provided. Possible medical
or psychosocial problems will be discussed, and the
patient can be referred to another professional (e.g. a psy-
chologist) if needed. There are two options for the fourth
meeting depending on whether the participant has
returned to work or not. If a participant has returned to
work, the fourth meeting will be scheduled approxi-
mately 1 month after the return-to-work, and advice
regarding continued employment will be provided. If the
participant has not returned to work, the fourth meeting
will take place a maximum of 14 months after baseline,
and the contents of the third meeting will be discussed.
Tamminga et al. BMC Cancer 2010, 10:345
http://www.biomedcentral.com/1471-2407/10/345
Page 4 of 92) Meeting with participant's occupational physician and 
supervisor
The occupational physicians will be asked to schedule a
meeting with the participant, the participant's supervisor,
and with himself/herself to make a return-to-work plan.
Medical information from the hospital regarding disease,
treatment, and long-term side effects as the identified
barriers to return-to-work and actions to remove these
barriers that were discussed with the nurse can be used as
a basis for this discussion. This meeting should be sched-
uled between the second and third meeting with the
nurse, which would be between the second and tenth
month after the first day of sick leave. The researcher will
request this meeting; the request will be attached to the
first letter from the treating physician to the occupational
physician. A return-to-work plan will contain the follow-
ing information: first day of work resumption, the num-
ber of hours the participant will work, the task(s) he/she
is going to perform, and with which steps patients will
increase working hours, working days and/or will do
additional or different tasks.
3) Enhancing communication between treating physician 
and occupational physician
In the Netherlands, patients must give their consent to
allow medical information to be sent from a treating phy-
sician to an occupational physician. A nurse will ask for
this consent from each participant during the first meet-
ing. If the participant gives consent, a copy of a letter
from their treating physician to their primary care physi-
cian (containing general medical information such as
diagnosis, prognosis, treatment plan, and outcome treat-
ment) will be sent to their occupational physician. Gen-
eral information about the study (including the
educational leaflet) will be attached to this letter. The
identified barriers to return-to-work and actions to
remove these barriers that were discussed with a nurse
will be sent by a nurse to an occupational physician.
Study design to evaluate the intervention
For the description of the design of our evaluation study,
we used the items of the CONSORT statement for
improving the quality of reporting randomised trials [24].
Organisation study
The study is designed as a randomised controlled trial
with a follow-up of 2 years. Cancer patients are asked to
participate at the hospital. The medical ethics committee
of the institution, the Academic Medical Center,
approved the study, and the local medical ethics commit-
tees of various participating hospitals advised positively
about the local feasibility of the study. Patients will sign
informed consent forms before participating in the study.
Recruitment of study population
The treating physician or nurse will inform the cancer
patients about the study when they visit the hospital to
discuss their treatment plans. The treating physician will
check each patient's eligibility by assessing the inclusion
and exclusion criteria and provide written information
about the study. Then, the researcher will contact the
patient by telephone to provide additional information
and schedule a meeting with the patient following a visit
to the hospital or at the patient's home. After the patient
has signed informed consent and filled out a baseline
questionnaire, he or she will be randomised to either the
control group or the intervention group.
Participants
Patients are eligible to participate when they have a pri-
mary diagnosis of cancer, will be treated with curative
intent, are employed at the time of diagnosis, are sick-
listed, and are between 18 and 60 years old. Treatment
with curative intent was defined as a 1 year survival rate
of approximately 80%. The exclusion criteria are: 1)
patients who are not able to speak, read or write Dutch
sufficiently well, 2) patients who have a severe mental dis-
order or other severe co-morbidity, 3) Primary diagnosis
of cancer has been made more than two months ago, 4)
patients who will receive primary treatment at another
hospital, and 4) patients who have a primary diagnosis of
testicular cancer, non-melanoma skin cancer or mela-
noma skin cancer. This last exclusion criterion has been
selected because, on average, these cancer patients do not
experience significant problems with return-to-work;
therefore, the intervention would not be useful for the
majority of this patient group [5,25].
Randomisation, blinding and treatment allocation
The researcher will carry out randomisation using the
computerised randomisation program ALEA [26]. Allo-
cation of each patient is definite in such a way that alloca-
tion concealment is not possible. Because, patients differ
significantly between the participating hospital depart-
ments in diagnosis and demographic factors, and because
these aspects, as well as age, are important prognostic
factors for return-to-work, [18] randomisation is strati-
fied by the treating hospital department and age to pre-
vent bias due to unequal randomisation. The cut-off age
for stratification is 50. To equalise group sizes, minimisa-
tion is applied. If a treating hospital department has more
than one nurse, participants in the intervention group
will only be seen by nurses who carry out the intervention
and vice versa. Participants, nurses, and researchers are
not blinded to group assignment. Because all follow-up
questionnaires will be filled out at home, no direct influ-
ence by the researchers is likely to occur.
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The calculation of sample size is based on two earlier
studies regarding return-to-work in cancer patients.
Based on the study by Spelten et al. [18] with consecutive
cancer patients, the expectation is that 18 months after
diagnosis 36% of patients will not have returned to work
[18] after care as usual in the control group. With regard
to the intervention group, the expectation is that 19% of
the patients will not have returned to work 18 months
after diagnosis [23], based on the study by Nieuwenhui-
jsen et al. [23]. Due to the inclusion and exclusion criteria,
a percentage of patients with relatively less severe return-
to-work problems will not be included in this study and
this may lead to less favourable return-to-work rates.
However, our intervention is more comprehensive than
in the study by Nieuwenhuijsen et al. [23] and thus the
expectation is that the percentages of patients that will
not have returned to work will be the same as in the study
by Nieuwenhuijsen et al. [23]. This indicates an Odds
Ratio of 0.41 of the intervention versus usual care for
higher percentages of patients that are not returned to
work, which is the same as an Odds Ratio of 2.4 of the
intervention versus care as usual for higher return-to-
work rates. Since, the incidence of outcome is more than
10%, the Odds Ratio overestimates the magnitude of the
association and therefore, we calculated the Relative Risk
based on the Odds Ratio [27]. This indicates a Relative
Risk of not returning to work of 0.53 of the intervention
versus usual care. Based on the PS Power and Sample size
Program, with a power of 80% and two-sided significance
level of p < 0.05, the sample size should be 109 patients in
every arm, for a total of 216 patients [28]. Assuming that
20% of the initial patients will be lost to follow-up during
the course of the study, 270 patients must be recruited to
gather 246 patients at 24 months. To account for at least
10% missing data at baseline, 300 patients are intended to
be included. Furthermore, a sample size of 300 will have
sufficient power to be able to control for the prognostic
factors in a Cox regression analysis since we assume that
5 to 10 variables will be included in the final model
[17,18] and a sample size of 10 per included factor in a
Cox regression analysis is considered sufficient [29].
Contamination
In departments with more than one nurse, nurses who
counsel participants in the intervention group will not
counsel participants in the control group, and vice versa.
Nurses who counsel participants in the intervention
group are asked not to discuss the content of the inter-
vention with nurses who counsel participants in the con-
trol group. In departments with only one nurse, this
separation is not possible. However, since all nurses in the
intervention group will need to extend their meeting for
the intervention, and since they all need to fill out a form
during each meeting, contamination between groups will
be diminished. It is unlikely that employees of the same
company will participate in the study; therefore, it is
unlikely that participants in the control group will receive
detailed information about the content of the interven-
tion. It is possible that participants in the intervention
group will discuss the content of the intervention with
those in the control group at the hospital in the waiting
room or during chemotherapy treatment. However, we
do not consider this possibility a serious risk of contami-
nation.
Participants will be able to use any co-intervention they
wish. Since it is likely that other vocational rehabilitation
programs will have a significant effect on return-to-work,
these co-interventions will be monitored by asking the
participants at the end of the intervention if they have
participated in any other vocational rehabilitation pro-
grams. Because the effect of other rehabilitation pro-
grams on return-to-work is unknown, these co-
interventions will not be assessed.
Usual care in the Netherlands
Employees who are diagnosed with cancer should be
guided according to the blueprint of evidence-based
guidelines of the Dutch Association of Occupational Phy-
sicians (NVAB) [30]. Furthermore, sick leave is covered in
the Netherlands by the Improved Gatekeepers Act, which
is in force during the first 2 years of sick leave. The act
states that a sick-listed employee cannot be discharged
and receives at least 70% of his/her wage. After 2 years of
sickness, the sick-listed employee will be assessed for dis-
ability pension. The Improved Gatekeepers Act states
that employers and sick-listed employees are responsible
for work resumption, which means that both parties can
be sanctioned. Furthermore, all sick-listed employees
should have an occupational physician who should legally
advise them about return-to-work.
Training nurses to carry out the intervention
The nurses who carry out the intervention will partici-
pate in a half-day training course. This training course
consists of education about the rights and obligations of
sick-listed employees according to the Improved Gate-
keepers Act and education about the return-to-work
problems of cancer patients. For instance, education
about the return-to-work rates of cancer patients, factors
that can have an impact on the return-to-work outcomes
(e.g. diagnosis, type of treatment, and work ability), and
the role of colleagues, supervisors, and occupational phy-
sicians. Furthermore, extensive practice is given at each
meeting by means of role-playing and discussions
between trainer and trainees. The training course will be
given by a trained psychologist and a researcher. For eval-
uation, all nurses are asked to give their opinions of the
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naire at the end of the course.
Outcomes
The primary outcome parameters are return-to-work and
quality of life. The secondary outcome parameters are
work ability, work limitations, study feasibility, and
direct/indirect costs of the intervention. The primary and
secondary outcomes will be assessed at baseline and at 6,
12, 18, and 24 months after baseline. Participants will fill
out the baseline questionnaires directly after signing the
informed consent forms. The other questionnaires will be
mailed with an enclosed free return envelope. It will take
participants approximately 30 minutes to complete each
questionnaire. The questionnaire has been pilot-tested
with healthy subjects and cancer patients.
Effect evaluation
The study's effectiveness will be determined on the basis
of the primary outcomes of return-to-work and quality of
life and the secondary outcomes of work ability and work
limitations, assessed at the long-term follow-up at 12
months and at the very long-term follow-up at 24
months. Prognostic factors will be taken into account in
the effect analysis only if there are imbalances between
the intervention group and the control group. Effective-
ness will be inferred if participants in the intervention
group will have a significantly shorter time to return-to-
work than participants in the control group and if at the
same time their quality of life does not significantly dete-
riorate. Return-to-work is measured both as the number
of calendar days between the first day of sick leave and
the first day at work (either part-time or full-time) sus-
tained for at least 4 weeks and as the rate of return-to-
work at follow-up. The first day of sick leave, the number
of calendar days until return-to-work, and the return-to-
work rates will be based on patient self-reporting on
questionnaires [23]. Quality of life will be assessed with
the SF-36 [31]. All subscales of the SF-36 will be taken
into account (physical functioning, role limitations due to
physical health problems, bodily pain, general health per-
ceptions, vitality, social functioning, role limitations due
to emotional problems, and general mental health). The
SF-36 has been validated in a sample of cancer patients,
and normative values have been determined [31]. Work
ability will be assessed with the first 3 questions of the
Work Ability Index (WAI) [32]. These questions concerns
the evaluation of current work ability compared to their
life time best and current physical and mental work abil-
ity with respect to their job demands. Acceptable mea-
sures for reliability and validity have been determined
[33,34]. Work limitations will be assessed on the basis of
the Work Limitation Questionnaire, where work limita-
tions are defined as being inversely related to productivity
[35]. This questionnaire consists of four different sub-
scales: work scheduling, physical demands, mental
demands/social demands, and output demands. The Eng-
lish version of the Work Limitation Questionnaire has
been proven valid and reliable in populations of several
chronic diseases [35] and cancer survivors [10,11,36]. The
validity and reliability assessments of the Dutch transla-
tion of the Work Limitation Questionnaire are currently
underway for healthy controls and cancer patients.
Process evaluation
Process evaluation is divided into the following parame-
ters: 1) feasibility of the procedure, 2) satisfaction with
the intervention, 3) participant compliance with the
intervention, 4) nurse adherence to the protocol, and 5)
evaluation of usual care. First, feasibility of the procedure
will be assessed by a researcher on the basis of a checklist
at the end of the study. Second, nurse and participant sat-
isfaction with the intervention will be assessed by a ques-
tionnaire. Third, patient compliance with the
intervention will be assessed by a questionnaire. Fourth,
nurse adherence to the protocol will be assessed by a
researcher on the basis of reports from the nurse. Fifth,
evaluation of usual care will be assessed on the basis of a
questionnaire and includes organisational factors such as
received support from the organisation and the occupa-
tional physician.
Economic evaluation
For the economic evaluation, the work-related costs to
society, the individual cancer patient, and the employer
will be taken into account, since everyone incurs costs
when an individual cancer patient does not return-to-
work [37]. In this way, the costs and benefits will be cal-
culated independently of those who bear these costs and
those who receive the benefits. For the intervention
group, direct costs such as the costs to carry out the
intervention, and indirect costs, such as absenteeism or
work productivity, lost earnings, and work adjustments
will be taken into account. For the control group direct
costs such as the costs to carry out care as usual, and indi-
rect costs, such as absenteeism or work productivity, lost
earnings, and work adjustments will be taken into
account. The direct costs will be determined by means of
the average nurse wage and the amount of time spent on
each participant. The nurse will record the duration of
each meeting at its completion. Indirect costs will be
obtained by a questionnaire. Absenteeism will be deter-
mined by means of days on sick leave and on income and
work productivity by the Work Limitation Questionnaire
and on income [35]. Furthermore, lost earnings will be
determined on the basis of the differences between
income at baseline and income at follow-up. Work adjust-
ments will be assessed by means of the cost of each work
adjustment.
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We have taken into account as prognostic factors, all fac-
tors that were significant related to time to return-to-
work in a prospective cohort study on the impact of can-
cer-and work-related factors on the return-to-work of
cancer patients [17,18]. Prognostic factors will be
assessed by questionnaires at all time points except for
diagnosis and treatment, which will be retrieved from
patient files. The prognostic factors include age, gender,
education, diagnosis, cancer treatment, number of work-
ing hours according to contract, physical workload as
measured by the Questionnaire Perception and Judge-
ment of Work (VBBA) [38], importance of work as mea-
sured by a Visual Analogue Scale (VAS-scale), fatigue as
measured by the Multidimensional Fatigue Inventory
(MFI) [39], depression as measured by the Centre for Epi-
demiologic Studies for Depression Scale (CES-D) [40],
co-morbidity, income, self-efficacy as measured by the
general self-efficacy scale (ALCOS) [41], and global qual-
ity of life as measured on a VAS-scale. The descriptive
factors include the number of days between the first day
of sick leave and inclusion in the study, marital status,
ethnicity [42], time since diagnosis, breadwinner status,
position at work, shift work, years in current position,
years of paid employment, and company size. These
descriptive factors will be measured only at baseline.
Statistical analysis
Effectiveness
All analyses, which will be performed to distinguish dif-
ferences between the control group and intervention
group, will be performed according to the intention-to-
treat principle. All baseline data and data regarding pri-
mary and secondary outcomes will be presented using
descriptive statistics. The number of days until partici-
pants' return-to-work will be analysed using the Kaplan-
Meier survival method, and differences between groups
will be tested with a log rank test. If necessary, the differ-
ences between the control group and the intervention
group will be adjusted with a Cox regression analysis for
confounders such as diagnosis and for the prognostic
parameters. Longitudinal multilevel analysis will be used
to examine differences between the control group and the
intervention group with regard to improvement of the
primary outcome of quality of life and the secondary out-
comes of work ability and work limitations.
Economic evaluation
The economic evaluation will be performed according to
the intention-to-treat principle. The direct and indirect
costs will be summed for each participant. Mean differ-
ences in direct, indirect, and total costs will be calculated
between the control group and the intervention group
using bootstrapping. Incremental cost-effectiveness
ratios will be calculated by assessing the ratio between
the differences in costs between the groups to the differ-
ences in return-to-work rates between the groups. These
ratios will be displaced in a cost-effectiveness plane, and
acceptability curves will be presented.
Discussion
There is a lack of effective work-directed interventions
specifically tailored to cancer patients. The aim of this
study is to develop an intervention that will be carried out
as a randomised controlled trial.
As a starting point for developing a new work-directed
intervention, the shared care model, adjusted for the
vocational rehabilitation setting, has been used. The
work-directed intervention involves: 1) 4 meetings with a
nurse at the treating hospital department to start early
vocational rehabilitation, 2) 1 meeting with the partici-
pant, occupational physician, and supervisor to make a
return-to-work plan, and 3) letters from a treating physi-
cian to an occupational physician to enhance communi-
cation. The aim of the work-directed intervention is to
improve cancer patients' care and to enhance their
return-to-work and quality of life.
Methodological considerations of the development and 
content of the intervention
Developmental considerations
In the literature, methods such as intervention mapping
are often used as tools for developing new interventions.
In this study, no such tools have been used; however, all of
the important ingredients to develop an intervention
have been employed, including the use of a model, litera-
ture, and expert knowledge. By putting this intervention
into practice, the quality of vocational rehabilitation
might improve due to the improved medical knowledge
of an occupational physician about each patient and
improved continuity of care [43].
Content considerations
Because we used a cancer care model and interviews with
health care professionals we think that we have taken
practical considerations into account that will improve
the intervention implementation. This resulted for exam-
ple in an extra burden on participants and health care
professionals that is in our view quite reasonable.
Methodological considerations of the study design
We used the items of the CONSORT statement for
improving the quality of reporting randomised trials as
guidance for the study protocol [24]. One drawback of
our study design is that in departments with one nurse,
the nurse might also give better guidance to participants
in the control group leading to contamination. One way
to prevent this kind of contamination is to randomise on
the hospital department level, so-called cluster randomis-
ation. In our case this had the following disadvantages.
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vocably lead to baseline differences in patient characteris-
tics, such as diagnosis, treatment, and age because
departments deal with specific cancer patients. These
baseline characteristics are the most important prognos-
tic factors for return-to-work [17,18] and differ signifi-
cantly between hospital departments in the Netherlands.
Although it is possible to correct for these baseline differ-
ences afterward, bias will always be apparent. Further,
nurses might invite a specific group of patients to partici-
pate in the study since they know in which group each
patient will come [44]. At last, psycho-oncology care dif-
fers between hospital departments; thus, the outcome
might be biased by these differences in usual care. The
drawback of our approach is of course contamination. To
reduce the likelihood of contamination, nurses must fill
out a process form for each patient in each meeting.
We choose not to perform a comprehensive cost effec-
tiveness evaluation in which all direct and indirect costs,
such as medical consumption are taken into account
because the expectation is that the intervention has no
effect on these costs. Therefore, the expectation is that
these medical costs are equally divided between groups
and therefore do not contribute to the cost analysis. In
addition, the aim of our work-directed intervention is to
improve participants' return-to-work and work produc-
tivity and to reduce absenteeism and lost earnings.
Therefore, we choose to perform the economic evalua-
tion on the basis of these work-related costs.
This study will provide information about the effective-
ness of our work-directed intervention on return-to-work
and quality of life. The results will be available in 2011.
Furthermore, the intention is to implement the interven-
tion in normal care if it has been shown effective.
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